Immunotherapy has revolutionised cancer treatment by providing significant survival advantages across a variety of cancers. It works by leveraging the body's immune system to detect and destroy cancer cells, marking a considerable departure from traditional cytotoxic therapies. Nonetheless, boosting immune activity can also disrupt immune tolerance, leading to immune-related adverse events (irAEs) that may affect multiple organs, including the eyes. Although ocular irAEs linked to immune checkpoint inhibitors are relatively rare, occurring in about 2.8–3.6% of patients treated, with dry eye and uveitis being the most common, they emphasise the need for awareness and understanding as these treatments become more widespread. This review aims to explain the mechanisms of immunotherapy-induced immune dysregulation, describe common and serious ocular side effects, and emphasise the importance of prompt diagnosis and management.